Empagliflozin clinical trials, in English

This is an umbrella study evaluating the how well it works and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages.

NCT03424005 · Official ClinicalTrials.gov record · Hoffmann-La Roche

A proof-of-concept compared with a dummy treatment trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

NCT05726032 · Official ClinicalTrials.gov record · Yale University

Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions.

NCT05972564 · Official ClinicalTrials.gov record · Vanderbilt University Medical Center

Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the how well it works and safety of treatment in patients hospitalized with heart failure.

NCT06024746 · Official ClinicalTrials.gov record · Colorado Prevention Center

Primary Objective: To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease (NDKD), on empagliflozin therapy. Primary Endpoint: We will assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

NCT06110130 · Official ClinicalTrials.gov record · Washington D.C. Veterans Affairs Medical Center

In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding their how well it works and safety in patients under chronic hemodialysis.

NCT06249932 · Official ClinicalTrials.gov record · National Taiwan University Hospital

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.

NCT06424288 · Official ClinicalTrials.gov record · Boehringer Ingelheim

The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.

NCT06430684 · Official ClinicalTrials.gov record · Ann & Robert H Lurie Children's Hospital of Chicago

Empagliflozin, a new class of diabetes medication, has demonstrated a reduction in renal function decline among patients with chronic kidney disease, regardless of their diabetes status. However, all previous studies excluded dialysis patients.

NCT06483074 · Official ClinicalTrials.gov record · Chinese University of Hong Kong

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce CVD events, including incident HF. SGLT2 is a glucose transport protein in the kidneys.

NCT06507657 · Official ClinicalTrials.gov record · University of Minnesota

The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomly assigned trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.

NCT06570473 · Official ClinicalTrials.gov record · University of Alberta

The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study.

NCT06642272 · Official ClinicalTrials.gov record · Herlev and Gentofte Hospital

The aim of this randomly assigned trial with a 2-by-2 factorial design is to test the how well it works of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones. Study interventions: * Empagliflozin 10 mg once daily per os for 36 months * Personalized dietary counseling for 36 months.

NCT06653738 · Official ClinicalTrials.gov record · Insel Gruppe AG, University Hospital Bern

Repaired Tetralogy of Fallot (rTOF) is the leading cause of congenital cyanotic heart disease worldwide, involving up to 7-10% of congenital heart disease. With advances in open-heart surgical repair techniques and medical therapies, there is a significant increase in patients with rTOF surviving till late adulthood.

NCT06668389 · Official ClinicalTrials.gov record · The University of Hong Kong

The study will assign participants to take either the medication, empagliflozin or a dummy treatment (placebo) for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

NCT06745063 · Official ClinicalTrials.gov record · VA Office of Research and Development

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study.

NCT06935370 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Some people are born with a birth defect where they only have one functioning ventricle (lower chamber) in their heart. This condition can be initially managed with a Fontan operation, but there is a risk of developing Fontan Circulatory Failure (FCF) later in life.

NCT06955260 · Official ClinicalTrials.gov record · Subodh Verma

Randomly assigned, triple-masked, parallel arm clinical trial of empagliflozin versus dummy treatment (placebo) in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

NCT06992440 · Official ClinicalTrials.gov record · Gustavo A Heresi, MD, MS

The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization. randomly assigned treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching dummy treatment (placebo) during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90.

NCT07038356 · Official ClinicalTrials.gov record · Christian Schulze

This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e.

NCT07055282 · Official ClinicalTrials.gov record · University of Chicago

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

NCT07064473 · Official ClinicalTrials.gov record · Boehringer Ingelheim

The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.

NCT07074418 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Nice

Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.

NCT07141355 · Official ClinicalTrials.gov record · University Hospital, Strasbourg, France

This prospective watch-and-measure (no experimental treatment required) study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

NCT07348484 · Official ClinicalTrials.gov record · Instituto de Investigación Biomédica de Salamanca

The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators selected the change in skeletal muscle oxidative capacity and posed the following scientific question: Does empagliflozin significantly improve the oxidative capacity of skeletal muscle?

NCT07771010 · Official ClinicalTrials.gov record · University Medical Centre Ljubljana

This study employs a prospective, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all you would be randomly assigned in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone dummy treatment (placebo) + mazdutide dummy treatment (placebo); Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide dummy treatment (placebo); Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone dummy treatment (placebo); Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone.

NCT07775846 · Official ClinicalTrials.gov record · Huijie Zhang

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomly assigned controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction.

NCT07776054 · Official ClinicalTrials.gov record · Samsung Medical Center

This study will see if treatment with empagliflozin or losartan can reduce the risk of kidney stone formation in patients with paraffin disease, a condition caused by the injection of paraffin oil into muscle tissue for cosmetic muscle enlargement. Paraffin disease can lead to chronic inflammation, disturbances in calcium regulation, high blood calcium levels, kidney stones, and impaired kidney function.

NCT07828002 · Official ClinicalTrials.gov record · Martin Blomberg Jensen

The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.

NCT07845630 · Official ClinicalTrials.gov record · Boehringer Ingelheim